These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 36607488)

  • 1. Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines.
    Ou B; Yang Y; Lv H; Lin X; Zhang M
    BioDrugs; 2023 Mar; 37(2):143-180. PubMed ID: 36607488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in Vaccine Adjuvants.
    Firdaus FZ; Skwarczynski M; Toth I
    Methods Mol Biol; 2022; 2412():145-178. PubMed ID: 34918245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research progress in the development of natural-product-based mucosal vaccine adjuvants.
    Gao Y; Guo Y
    Front Immunol; 2023; 14():1152855. PubMed ID: 37090704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of thermostable vaccine adjuvants.
    Qi Y; Fox CB
    Expert Rev Vaccines; 2021 May; 20(5):497-517. PubMed ID: 33724133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances and challenges in mucosal adjuvant technology.
    Newsted D; Fallahi F; Golshani A; Azizi A
    Vaccine; 2015 May; 33(21):2399-405. PubMed ID: 25865473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine adjuvants: mechanisms and platforms.
    Zhao T; Cai Y; Jiang Y; He X; Wei Y; Yu Y; Tian X
    Signal Transduct Target Ther; 2023 Jul; 8(1):283. PubMed ID: 37468460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine Adjuvants: Selection Criteria, Mechanism of Action Associated with Immune Responses and Future Directions.
    Habib A; Anjum KM; Iqbal R; Jaffar G; Ashraf Z; Khalid MS; Taj MU; Zainab SW; Umair M; Zohaib M; Khalid T
    Iran J Immunol; 2023 Mar; 20(1):1-15. PubMed ID: 36917475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives.
    Zeng Y; Zou F; Xia N; Li S
    Expert Rev Vaccines; 2023; 22(1):681-695. PubMed ID: 37496496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants.
    Hioki K; Hayashi T; Natsume-Kitatani Y; Kobiyama K; Temizoz B; Negishi H; Kawakami H; Fuchino H; Kuroda E; Coban C; Kawahara N; Ishii KJ
    Front Immunol; 2022; 13():847616. PubMed ID: 35663999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laser vaccine adjuvants: Light-augmented immune responses.
    Maki Y; Kashiwagi S; Kimizuka Y
    Vaccine; 2021 Nov; 39(46):6805-6812. PubMed ID: 34666921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentials of saponins-based adjuvants for nasal vaccines.
    Chen K; Wang N; Zhang X; Wang M; Liu Y; Shi Y
    Front Immunol; 2023; 14():1153042. PubMed ID: 37020548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.
    Jin Z; Gao S; Cui X; Sun D; Zhao K
    Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Materials engineering strategies for cancer vaccine adjuvant development.
    Zhang X; Yang B; Ni Q; Chen X
    Chem Soc Rev; 2023 May; 52(9):2886-2910. PubMed ID: 37014050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New-age vaccine adjuvants, their development, and future perspective.
    Verma SK; Mahajan P; Singh NK; Gupta A; Aggarwal R; Rappuoli R; Johri AK
    Front Immunol; 2023; 14():1043109. PubMed ID: 36911719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvants for human vaccines--current status, problems and future prospects.
    Gupta RK; Siber GR
    Vaccine; 1995 Oct; 13(14):1263-76. PubMed ID: 8585280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of gut environment-mediated control system of host immunity in the development of vaccine adjuvants.
    Liu Z; Hosomi K; Kunisawa J
    Vaccine; 2022 Aug; 40(36):5399-5403. PubMed ID: 35918205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvants for cancer mRNA vaccines in the era of nanotechnology: strategies, applications, and future directions.
    Cao LM; Yu YF; Li ZZ; Zhong NN; Wang GR; Xiao Y; Liu B; Wu QJ; Feng C; Bu LL
    J Nanobiotechnology; 2024 Jun; 22(1):308. PubMed ID: 38825711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunostimulant plant proteins: Potential candidates as vaccine adjuvants.
    Nazeam JA; Singab ANB
    Phytother Res; 2022 Dec; 36(12):4345-4360. PubMed ID: 36128599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What are the limits of adjuvanticity?
    Del Giudice G; Podda A; Rappuoli R
    Vaccine; 2001 Oct; 20 Suppl 1():S38-41. PubMed ID: 11587808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine adjuvants: current status, research and development, licensing, and future opportunities.
    Cui Y; Ho M; Hu Y; Shi Y
    J Mater Chem B; 2024 May; 12(17):4118-4137. PubMed ID: 38591323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.